
TD Cowen Insights
Drugging The Undruggable: CEO Mike Cloonan's Journey To Sionna Therapeutics
Recorded on 03/03/25
TD Cowen senior biotech analyst Ritu Baral speaks with SION's CEO Mike Cloonan at TD Cowen's 45th Annual Health Care Conference to discuss his journey becoming a start-up biotech CEO and leading SION through a successful IPO in turbulent markets. Cloonan's path to CEO started with early career roles and skill development throughout all functions of a company – commercial, R&D, and SG&A. Joining Sionna with prior experience at large and mid-cap companies, Cloonan emphasizes how his nimbleness and ability to prioritize goals has helped him successfully lead a small start-up through a smooth IPO. Cloonan discusses SION's ability to "drug the undruggable" through targeting NBD1 as a main reason he decided to lead SION, while also highlighting the importance of leading with intention to identify the unmet need of patients.
https://go.td.com/PodcastDisclosure